Elucidating the clinical and immunological value of m6A regulator-mediated methylation modification patterns in adrenocortical carcinoma

Abstract

N6-methyladenosine methylation (m6A) is a common type of epigenetic alteration that prominently affects the prognosis of tumor patients. However, it is unknown how the m6A regulator affects the tumor microenvironment (TME) cell infiltration in adrenocortical carcinoma (ACC) and how it affects the prognosis of ACC patients yet. The m6A alteration patterns of 112 ACC patients were evaluated, furthermore, the association with immune infiltration cell features was investigated. The unsupervised clustering method was applied to typify the m6A alteration patterns of ACC patients. The principal component analysis (PCA) technique was taken to create the m6A score to assess the alteration pattern in specific malignancies. We found two independent patterns of m6A alteration in ACC patients. The TME cell infiltration features were significantly in accordance with phenotypes of tumor immune-inflamed and immune desert in both patterns. The m6Ascore also served as an independent predictive factor in ACC patients. The somatic copy number variation (CNV) and patients prognosis can be predicted by m6A alteration patterns. Moreover, the ACC patients with high m6A scores had better overall survival (OS) and higher efficiency in immune checkpoint blockade therapy. Our work demonstrated the significance of m6A alteration to the ACC patients immunotherapy. The individual m6A alteration patterns analysis might contribute to ACC patients prognosis prediction and immunotherapy choice.

Unveiling the unexplored novel signatures for osteoporosis via a detailed bioinformatics and molecular experiments based approach

“…According to earlier studies, the down-regulation of the SF3A1 gene is associated with Paget's disease of bone (PDB) [40]. The protein encoded by the ATXN2L gene belongs to the spinocerebellar ataxia (SCAs) family, which is mainly associated with neurodegenerative disorders [41,42]. To the best of our knowledge, the role of this gene has not been explored in OP so far, we are the first to report the down-regulation of this gene in OP patients.…”

METTL14-Mediate the Biological Effects of EMT in Bladder Cancer Cells by Methylating SOX4 mRNA with m6A

“…[19][20][21] In addition, m6A affects tumour expression, immunotherapy, and targeted therapy by altering programmed cell death, metabolism, drug resistance, and oncogenes. 22,23 Here, to further verify the targeted relationship between METTL14 and SOX4, this study used RIP and MeRIP-qPCR to demonstrate that m6A-modified SOX4 was the downstream target of METTL14. The experimental findings revealed that METTL14 exerts a negative regulatory effect on SOX4 expression, with SOX4 expression being modulated by METTL14-mediated m6A methylation.…”

Decoding the DSCC1 gene as a pan-cancer biomarker in human cancers via comprehensive multi-omics analyses

“…STRING (Search Tool for the Retrieval of Interacting Genes/Proteins) is a comprehensive database that facilitates the exploration of protein-protein interactions [26,27]. It integrates diverse interaction sources, including experimental data and computational predictions, offering a holistic view of the interactome landscape.…”